 |
Nicholas, M. Kelly, MD PhD
Assistant Professor, Departments of Neurology, Medicine & Surgery
Director, Clinical Neuro-Oncology Program
Director, Neuro-Oncology Fellowship Program
| Address: |
5841 S. Maryland Ave., MC 2030
Chicago, IL 60637-1470 |
| Telephone: |
773-834-9026 |
| Secretary: |
Lydia Madrigal
|
| Patient Calls: |
773-702-6222 |
| Fax: |
773-702-9076 |
|
|
Education & Training
- Ph.D., University of Chicago
- M.D., University of Chicago
- Internship, Evanston Hospital
- Residency, University of Chicago
- Fellowship, University of California, San Francisco
- Board Certified in Neurology
- Board Certified in Psychiatry
Clinical & Research Interests
- Dr. Nicholas completed a combined MD-PhD program at the University of Chicago, receiving his doctorate from the Committee on Immunology. Following residency training in neurology, again at the University of Chicago, he completed fellowship training in neuro-oncology at the University of California, San Francisco. Dr. Nicholas has since served on the faculty of both institutions where he received training. He is currently Director of the Neuro-Oncology Service in the Brain Tumor Center and a member of both the Neurology and Medicine (Hematology-Oncology) Departments at the University. Dr. Nicholas coordinates the care of brain tumor patients and assists in managing the neurological complications of cancer through his activities in several clinics and a formal neuro-oncology consult service. He oversees a weekly multi-disciplinary neuro-oncology seminar. Dr. Nicholas develops and supervises brain tumor clinical trials and interacts with several research laboratories in an effort to advance the field of neuro-oncology. Residents in the Department of Neurology are offered elective rotations in neuro-oncology during their training. They are also closely involved in the in-patient management of brain tumor patients. Dr. Nicholas also directs a Neuro-Oncology Fellowship Program, described in the Education sectdion of this website.
Teaching
- Director, Neuro-Oncology Fellowship Program.
Selected Publications
- Liang Y, Diehn M, Watson N, Bollen AW, Aldape KD, Nicholas MK, Lamborn KR, Berger MS, Botstein D, Brown PO, Israel MA. Gene expression pro?ling reveals molecularly and clinically distinct subtypes of glioblastoma multiforme. Proc Natl Acad Sci U S A. 2005 Apr 19;102(16):5814-9.
- Chang SM, Lamborn KR, Malec M, Larson D, Wara W, Sneed P, Rabbitt J, Page M, Nicholas MK, Prados MD. Phase II study of temozolomide and thalidomide with radiation therapy for newly diagnosed glioblastoma multi-forme. Int J Radiat Oncol Biol Phys. 2004 Oct 1;60(2):353-7.
- Larson DA, Suplica JM, Chang SM, Lamborn KR, McDermott MW, Sneed PK, Prados MD, Wara WM, Nicholas MK, Berger MS. Permanent iodine 125 brachytherapy in patients with progressive or recurrent glioblastoma multiforme. Neuro-oncol. 2004 Apr;6(2):119-26.
- Prados MD, Yung WK, Jaeckle KA, Robins HI, Mehta MP, Fine HA, Wen PY, Cloughesy TF, Chang SM, Nicholas MK, Schiff D, Greenberg HS, Junck L, Fink KL, Hess KR, Kuhn J; North American Brain Tumor Consortium study. Phase 1 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study. Neuro-oncol. 2004 Jan;6(1):44-54
- Puduvalli VK, Yung WK, Hess KR, Kuhn JG, Groves MD, Levin VA, Zwiebel J, Chang SM, Cloughesy TF, Junck L, Wen P, Lieberman F, Conrad CA, Gilbert MR, Meyers CA, Liu V, Mehta MP, Nicholas MK, Prados M; North American Brain Tumor Consortium. Phase II study of fenretinide (NSC 374551) in adults with recurrent malignant gliomas: A North American Brain Tumor Consortium study. J Clin Oncol. 2004 Nov 1;22(21):4282-9.
Back to Top |
|
|